


# Genomic Therapies Are Set to Revolutionize Medicine

Gene therapy has made unprecedented progress with a broad sets of approaches and diseases addressed



# Genomic Therapies Are Set to Revolutionize Medicine

**WHITELAB**  
GENOMICS

More than **20** genomic therapies  
already approved

## Hundreds

of genomic therapies  
in development

The genomic medicine market is set  
to reach **\$40bn** in 2024 and  
**\$1 Trillion** at maturity

### *But...*


- R&D uncertainty
- Manufacturing and scaling
- Immunogenicity
- Specificity and selectivity
- Undesired off-target effects
- Limited packaging capacity
- Viability in human
- ...

Genomic medicine show significant promise but need substantial innovation to unlock full potential for patients. Scaling digital and analytics in discovery and R&D is part of the solution.



# We accelerate R&D for Genomic Medicine

**WHITELAB**  
GENOMICS



# We are capturing the emerging AI opportunity in Genomic Medicine

**WHITELAB**  
GENOMICS

## AI-Enabled Drug Discovery

### Exscientia

1<sup>st</sup> AI-designed drug molecule entering human clinical trials (CT)

### AlphaFold

DeepMind's AI system for protein structure predictions

### Insilico Medicine

Phase I CT for the 1<sup>st</sup> AI-discovered molecule based on an AI-discovered novel target

### Advent of chatgpt

Generative AI

2019-----2020-----2021-----2022-----2023-----▶

#### Dev stage 1 : Data identification & collection

Text based, biological and experimental data

#### Dev stage 2 : AI knowledge development

Data curation and ontologies

#### Dev stage 3 : Predictive modeling

Sequences, expression patterns and regulation, pathways, protein- function, cellular phenotypes



**WHITELAB**  
GENOMICS



Collaborations with Genethon and an INSERM laboratory expert in the pre-clinical development of gene therapies

Series A fundraising



1<sup>st</sup> partnership with leading pharmaceutical company

+25 employees,  
10 PhDs





# About us: 25+ people including 10+ PhD

**WHITELAB**  
GENOMICS

## CO-FOUNDERS

### David Del Bourgo, CEO

- VP marketing et ventes chez Genomic Vision
- Directeur marketing et ventes chez Theraclion
- Développement commercial, marketing et ventes dans de grandes organisations mondiales de soins de santé (GE Healthcare, Orbotech, Master en génie biomédical, Université de Technologie de Compiègne (France))
- MBA de l'Université de Chicago

### Julien Cottineau, CSO

- Application scientist senior chez Genomic Vision
- Chercheur postdoctoral à l'Université Rockefeller et à l'Hôpital Necker sur les déficiences immunitaires complexes humaines dans le laboratoire de J-L Casanova
- Doctorat en génétique, biologie moléculaire et immunologie à l'Université Pierre et Marie Curie, avec mention honorifique.

### Lucia Cinque, Board

- Directrice Innovation Wörwag (En poste)
- Directrice produit et innovation chez Genomic Vision
- VP Product & Innovation Endodiag
- Ecole Normale Supérieure, Politecnico di Milano, Polytechnique Montréal

## TEAM (MANAGERS)

**Oscar de Felice, PhD**  
Data Scientist lead  
< Imperial College, Generali

**Jean-Philippe Buffet, PhD**  
Biology lead  
< AgroParisTech, Pasteur, INRS

**Dylan Serillon, PhD, Pharm D**  
Structural Biology Lead  
< Univ Barcelona, Sanofi

**Jérémie Kalfon**  
Computational Biology Lead  
< Harvard, MIT, Broad Inst

**Timothé Cynober, Pharm D**  
Business Development Manager  
< Institut Curie, Novartis, VCLS

**Morgane Colléaux-Royer**  
Product Manager  
< Sanofi, Central Supélec

## SCIENTIFIC AND STRATEGIC BOARD

**Nicole Paulk, PhD**  
Former assistant professor USCF  
CEO SIREN Biotechnology

**Magali Richard, PhD**  
Scientific Advisor  
CEO Home Biosciences

**Jean-Pascal Tranie**  
Aloe Private Equity Partner

**Laurent van Lerberghe**  
Investor, Digital Health | Sanofi,  
Abbott, BCG Veteran



**52% male/female  
ratio**

